• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Study: VR-AI Therapy Cuts Night Flashes in Half for Cancer Patients

by Fred Pennic 02/21/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

 Study: VR-AI Therapy Cuts Night Flashes in Half for Cancer Patients

A new clinical study from VRHealth cites that breast cancer patients reduced hot flashes and night sweats by 50% using VR-AI therapy coaching environment. In addition, study participants reported significant improvements in their sleep quality and fewer disruptions to their daily lives following a three-week experiment with the VR solution. VRHealth is a digital health company focused on helping clinicians better manage their patients’ care via specialized virtual reality (VR) technology solutions and data analysis.

CBT for Hot Flashes Application

The clinical study conducted by VRHealth evaluated the efficacy of the therapist, which offers a psychological intervention based on cognitive behavioral therapy and mindfulness-based stress reduction. Breast cancer patients and survivors frequently experience hot flashes and night sweats as a result of chemotherapy or endocrine therapy, which cause changes to hormonal levels. Often distressing and embarrassing, hot flashes interfere with daily life, while night sweats lead to difficulty sleeping and subsequent fatigue—side effects disturbing enough to hinder compliance with anticancer therapies.

The study collected and analyzed demographic, clinical, physiological, and patient-reported outcome data during a ten-month period in 2018. Study participants wore VR goggles every day for 24 days in order to experience the virtual reality of a completely immersive, 360-degree snowy winter scene, dubbed Frosty. They were surveyed before and after the AI-VR intervention to assess their physical and psychological symptoms related to stress, sleep quality, and quality of life.

VR-AI Clinical Study Key Findings

The findings indicate that after daily exposure to the cold-looking AI-VR virtual wintertime world, the breast cancer patients reported 50 percent fewer hot flashes and night sweats. They also found that occurrences were less intense, the psychological distress related to health concerns was diminished, and the level of interference with their daily activities was lowered.

 

“This clinical research report shows that we’ve developed a highly effective solution for the hot flashes that plague breast cancer patients and survivors, to the extent of improving their overall quality of life,” says VRHealth CEO Eran Orr. “The results validate our protocol for alleviating difficult symptoms with a virtual reality intervention that is therapy-based, non-pharmaceutical, and easy to use.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Therapeutic Virtual Reality, Virtual Reality, VRHealth

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |